Effect of Low Dose 5-Fluorouracil and Cisplatin Intra-arterial Infusion Chemotherapy in Advanced Hepatocellular Carcinoma with Decompensated Cirrhosis.
- Author:
Tae Young LIM
1
;
Jae Youn CHEONG
;
Sung Won CHO
;
Sung Jun SIM
;
Jong Su KIM
;
Sung Jun CHOI
;
Jeong Woo CHOI
;
Hyeok Choon KWON
;
Kee Myung LEE
;
Jai Keun KIM
;
Je Hwan WON
;
Byung Moo YOO
;
Kwang Jae LEE
;
Ki Baik HAHM
;
Jin Hong KIM
Author Information
1. Department of Gastroenterology, Genomic Research Center for Gastroenterology, Ajou University School of Medicine, Suwon, South Korea. jaeyoun2@dreamwiz.com
- Publication Type:Original Article ; English Abstract
- Keywords:
Liver cirrhosis;
Hepatocellular carcinoma;
Thrombosis, venous;
Infusion;
intra-arterial;
Chemotherapy
- MeSH:
Venous Thrombosis/complications;
Survival Rate;
Portal Vein;
Palliative Care;
Middle Aged;
Male;
Liver Neoplasms/complications/*drug therapy/mortality;
Liver Cirrhosis/complications;
*Infusions, Intra-Arterial;
Humans;
Fluorouracil/administration & dosage;
Female;
Disease-Free Survival;
Cisplatin/administration & dosage;
Carcinoma, Hepatocellular/complications/*drug therapy/mortality;
Antineoplastic Combined Chemotherapy Protocols/*therapeutic use;
Aged;
Adult
- From:The Korean Journal of Hepatology
2006;12(1):65-73
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
BACKGROUND/AIMS: Advanced hepatocellular carcinoma (HCC) with portal vein thrombosis (PVT) has a poor prognosis. The aim of this study was to evaluate the efficacy and safety of repeated arterial infusions of low dose cisplatin and 5-fluorouracil (FU) in patients with advanced HCC with decompensated cirrhosis. METHODS: Between January 1995 and December 2003, a total of 79 decompensated cirrhotic patients having HCC and PVT were enrolled and divided into 2 groups. Group 1 (n=40) received intra-arterial infusion chemotherapy with cisplatin (10 mg for 5 days) and 5-FU (250 mg for 5 days) via an implanted chemoport every 4 weeks' and group 2 (n=39) was managed with only conservative treatment. RESULTS: The two groups were well matched with respect to the features relating to the prognosis, including age, gender and the Child- Pugh class. Although diffuse tumor involvement, main portal vein tumor thrombosis and bi-lobar involvement were more frequent in group 1, the median survival period of group 1 was significantly longer than group 2 (5 months vs. 3 months, respectively, P=0.016). Also, the 1-year survival rate of group 1 (7.5%) was higher than that of group 2 (5.1%) (P=0.016). When we analyzed the patients with the Child class B, the survival benefits of intra-arterial chemotherapy were more significant (P=0.008). CONCLUSIONS: Intra-arterial chemotherapy consisting of low dose 5-FU and cisplatin achieved favorable results for advanced HCC patients who had decompensated cirrhosis, and it showed better survival in selected patients. This therapy may be useful as a palliative treatment for HCC patients with decompensated cirrhosis.
